.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Cipla
Merck
McKesson
Healthtrust
Cerilliant
QuintilesIMS
AstraZeneca
Mallinckrodt
Cantor Fitzgerald

Generated: September 25, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Olopatadine formulations for topical nasal administration
Abstract: Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine.
Inventor(s): Singh; Onkar N. (Arlington, TX), Wall; G. Michael (Fort Worth, TX), Jani; Rajni (Fort Worth, TX), Chowhan; Masood A. (Arlington, TX), Han; Wesley Wehsin (Arlington, TX)
Assignee: Novartis AG (Basal, CH)
Application Number:11/703,373
Patent Claims: 1. A topically administrable, aqueous, nasal spray solution composition consisting of a) 0.665% (w/v) olopatadine hydrochloride; b) a phosphate salt in an amount equivalent to 0.4-0.6% (w/v) dibasic sodium phosphate, wherein the phosphate salt selected from the group consisting of monobasic sodium phosphate; dibasic sodium phosphate; tribasic sodium phosphate; monobasic potassium phosphate; dibasic potassium phosphate; and tribasic potassium phosphate; c) 0.35-0.45% (w/v) NaCl; d) one or more pH-adjusting agents in an amount sufficient to cause the composition to have a pH of 3.6-3.8, wherein the pH-adjusting agents are selected from the group consisting of HCl and NaOH; e) 0.005-0.015% (w/v) benzalkonium chloride; f) 0.005-0.015% (w/v) edetate disodium; and g) water; wherein the composition has an osmolality of 260-330 mOsm/kg.

2. A topically administrable, aqueous, nasal spray solution composition consisting of a) 0.665% (w/v) olopatadine hydrochloride; b) 0.4-0.6% (w/v) dibasic sodium phosphate; c) 0.35-0.45% (w/v) NaCl; d) one or more pH-adjusting agents in an amount sufficient to cause the composition to have a pH of 3.6-3.8, wherein the pH-adjusting agents are selected from the group consisting of HCl and NaOH; e) 0.01% (w/v) benzalkonium chloride; f) 0.01% (w/v) edetate disodium; and g) water; wherein the composition has an osmolality of 260-330 mOsm/kg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Deloitte
Cerilliant
Teva
Moodys
Johnson and Johnson
Argus Health
Farmers Insurance
US Department of Justice
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot